Roche Holding AG (RO)

246.00
0.00(0.00%)
  • Volume:
    0
  • Bid/Ask:
    245.80/246.40
  • Day's Range:
    244.80 - 248.00
  • Type:Equity
  • Market:Germany
  • ISIN:CH0012032113
  • WKN:851311

RO Overview

Prev. Close
245.8
Day's Range
244.8-248
Revenue
60.56B
Open
246.4
52 wk Range
0-0
EPS
-
Volume
0
Market Cap
276.73B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
2,891
P/E Ratio
-
Beta
-
1-Year Change
0%
Shares Outstanding
800,403,291
Next Earnings Date
-
What is your sentiment on Roche Holding?
or
Vote to see community's results!

Roche Holding AG News

Roche Holding AG Analysis

Roche Holding AG Company Profile

Roche Holding AG Company Profile

Employees
100920

Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women’s health. In addition, the company supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. It has collaboration with Gilead Sciences, Inc. for COVID-19; and a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza. The company also has a collaboration with Bristol Myers Squibb to advance personalized healthcare through digital pathology solutions. The company was founded in 1896 and is headquartered in Basel, Switzerland.

Read More

Technical Summary

Type
Daily
Weekly
Monthly
Moving Averages
Technical Indicators
Summary
  • A large pharmaceutical company, by the name of R. , is pushing down the value of the Spanish company's Pharmamar share price through the funds Consonance Capital and Great Point Partners, so that the biotech company accepts its offer of more than 4500 million dollars.According to this pharma, Pharmamar's products have a great future in oncology and virology, and would be fully engaged in its search for new drugs.
    1
    • 13.11.2020. CHMP recommends EU approval of Roche’s Xofluza® (baloxavir marboxil) for the treatment of influenza. This CHMP recommendation brings patients with influenza one step closer to potentially benefiting from Xofluza’s oral one-dose regimen, setting adults and adolescents on the path to feeling better sooner compared to placebo,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We believe that access to effective antivirals for influenza, and particularly their use in the prophylactic setting, could help reduce the strain of the COVID-19 pandemic on healthcare systems in Europe.
      0
      • Just like Biolidics. they get approval for Covid19 tests kits in USA
        0
        • i dont know
          0
          • is the historical price adjusted for stock splits?
            0
            • i dont know
              0